Processing

Please wait...

Settings

Settings

Goto Application

1. WO2002037937 - ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS

Publication Number WO/2002/037937
Publication Date 16.05.2002
International Application No. PCT/US2001/049952
International Filing Date 07.11.2001
Chapter 2 Demand Filed 06.06.2002
IPC
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07C 257/18 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
257Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
10with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
18having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
C07D 207/16 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
04having no double bonds between ring members or between ring members and non-ring members
10with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/60 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
211Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
06having no double bonds between ring members or between ring members and non-ring members
36with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 223/06 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
223Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
02not condensed with other rings
06with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 401/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
CPC
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 37/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
A61P 7/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
C07B 2200/07
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
2200Indexing scheme relating to specific properties of organic compounds
07Optical isomers
C07C 257/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
257Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
10with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
18having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
Applicants
  • BRISTOL-MYERS SQUIBB COMPANY [US]/[US] (AllExceptUS)
  • BISACCHI, Gregory, S. [US]/[US] (UsOnly)
  • SUTTON, James, C., Jr. [US]/[US] (UsOnly)
  • WU, Shung, C. [US]/[US] (UsOnly)
Inventors
  • BISACCHI, Gregory, S.
  • SUTTON, James, C., Jr.
  • WU, Shung, C.
Agents
  • ALGIERI, Aldo, A.
Priority Data
60/246,39107.11.2000US
60/246,39207.11.2000US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS
(FR) DERIVES D'ACIDES UTILISES COMME INHIBITEURS DE LA SERINE PROTEASE
Abstract
(EN)
Compounds of formula I and II, or pharmaceutically-acceptable salts thereof , are useful as inhibitors of Factor VIIa, Factor IXa, Factor Xa, Factor FXIa, tryptase, and urokinase, wherein ring B is phenyl or pyridyl, L is a linker, and R1 R27, W, Z1 , and Z2 are as defined in the specification.
(FR)
L'invention porte sur des composés des formules (I) et (II), ou sur leurs sels acceptables d'un point de vue pharmaceutique. Ces composés sont utiles comme inhibiteurs des facteurs VIIa, IXa, Xa, FXIa, tryptase et urokinase, le noyau B étant un phényle ou un pyridyle, L étant un lieur et R1 - R27, W, Z1, et Z2 étant définis dans la demande.
Latest bibliographic data on file with the International Bureau